Expert Scientific Advisory Committee (ESAC) [1]
MMV’s Expert Scientific Advisory Committee (ESAC) helps to identify the best projects worthy of inclusion in the portfolio and continues to monitor progress through an annual review of all projects. This committee consists of experts from both industry and academia and covers the full range of expertise required to assess projects that are engaging in the extremely complex process of drug research and development.
ESAC Members
Dr Tesfaye Biftu Distinguished professor, National institute of pharmaceutical sciences, ASTU, Adama, Ethiopia
Dr Nick Cammack Former Senior Vice-President and Head, Medicines Development Campus for Diseases of the Developing World at GSK, Tres Cantos, Spain
Sir Simon Campbell Former SVP for WW Discovery, Pfizer, organic chemist, UK
Robert Clay Consultant/Managing Director, Highbury Regulatory Science Limited; and Board Member (President 2017) at TOPRA, UK
Dr Anne Cooper Programme Director, Sosei Heptares, UK
Prof Brian Cox Professor of Pharmaceutical Chemistry, University of Sussex, School of Life Sciences, UK
Ms Delese Mimi Darko Chief Executive Officer, Food and Drugs Authority, Ghana
Dr Monica Hemben Eimunjeze Director Registration & Regulatory Affairs Directorate, National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria
Dr Rick M. Fairhurst Senior Safety Physician, R&D Oncology, AstraZeneca
Prof Daniel Goldberg Professor and Co-Chief, Division of Infectious Diseases Department of Medicine Washington University, USA
Dr Tim Hammond Independent Pharmaceutical Preclinical Safety Consultant at Preclinical Safety Consulting Ltd, UK
Dr Laurent Hennequin Research Director, Galderma R&D, La Tour de Peilz, Switzerland
Dr Marcus Lacerda Public Health Specialist, Fiocruz, Brazil
Prof John Lambert Chief Medical Officer, Global Head Medical Affairs and Consulting, PAREXEL International – Early Phase, UK
Dr Mary Mader Research Fellow, Discovery Chemistry Research and Technologies, Eli Lilly and Company, USA
Dr John Pottage Chief Scientific and Medical Officer, ViiV Healthcare; and Co-Chairman MMV ESAC (Development), USA
Dr Robert Riley Executive Vice President, Drug Discovery, Evotec, UK
Dr Esperança Sevene, Senior Research Fellow, Manhiça Health Research Centre, Mozambique
Prof Dennis Shanks Director, Australian Defence Force Malaria and Infectious Disease Institute, Australia
Dr Peter Siegl, Siegl Pharma Consulting, USA
Dr Shailja Singh, Associate Professor, Special Centre for Molecular Medicine, Jawaharlal Nehru University, India
Dr Sodiomon Sirima Centre National de Recherche et de Formation sur le Paludisme (CNRFP), Ouagadougou, Burkina Faso
Prof Dennis Smith Former Vice President, PGRD, Pfizer, Kent, UK
Dr Jane Stewart Reproductive Toxicology Associate, ApconiX, UK
Dr John R.J. Surtees Managing Partner, Berzelius Integrated Solutions, Belgium
Dr Melissa Tassinari, PhD DABT, Former Senior Clinical Advisor, Food and Drug Administration, USA
Dr Klaus Urbahns Head of Discovery and Development Technologies at Merck Group, Germany
Dr Elizabeth Vadas President, InSciTech Inc. Canada
Prof Stephen Ward Deputy Director, Liverpool School of Tropical Medicine, UK
Dr Michael Witty Drug Discovery Consultant and former Vice-President Pfizer R&D; Co-Chairman MMV ESAC (Discovery), UK
Dr Dyann Wirth Director, Harvard Malaria Initiative, Harvard School of Public Health, USA
Dr Taiyin Yang Executive Vice President, Pharmaceutical Development and Manufacturing, Gilead Sciences, USA
Dr Takeshi Yura Vice President Medicinal Chemistry, Jubilant Biosys Ltd, India